LYBALVI
NDC product · U.S. Food and Drug Administration (openFDA) · United States
-
Product NDC
65757-652 -
Package NDC
65757-652-41 -
Package NDC
65757-652-42 -
Application number
NDA213378 -
SPL ID
44ae69cc-b9a6-4658-90fa-1dbef1e97eb4 -
SPL set ID
32ffddd1-4e2b-45d9-9b36-bb730167ec80 -
UNII
0AJQ5N56E0 -
UNII
N7U69T4SZR -
RxCUI
2570392 -
RxCUI
2570398 -
RxCUI
2570399 -
RxCUI
2570401 -
RxCUI
2570402 -
RxCUI
2570404 -
RxCUI
2570405 -
RxCUI
2570407
What the source publishes
- Labeler
- Alkermes, Inc.
- Active ingredients
- olanzapine and samidorphan L-malate
- Form
- TABLET, FILM COATED
- Routes
- ORAL
- Administrative status
- present-in-source-snapshot
- Marketing status
- NDA
- Product type
- HUMAN PRESCRIPTION DRUG
- Prescription
- Prescription or restricted
Names this record is found by
Complete source data
{
"name": "LYBALVI",
"splId": "44ae69cc-b9a6-4658-90fa-1dbef1e97eb4",
"labels": [
{
"setId": "32ffddd1-4e2b-45d9-9b36-bb730167ec80",
"labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32ffddd1-4e2b-45d9-9b36-bb730167ec80",
"labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=32ffddd1-4e2b-45d9-9b36-bb730167ec80"
}
],
"routes": [
"ORAL"
],
"labeler": "Alkermes, Inc.",
"finished": true,
"packaging": [
{
"sample": true,
"description": "1 BOTTLE in 1 CARTON (65757-652-41) / 7 TABLET, FILM COATED in 1 BOTTLE",
"package_ndc": "65757-652-41",
"identifierStatus": "well-formed",
"marketing_start_date": "20210920"
},
{
"sample": false,
"description": "1 BOTTLE in 1 CARTON (65757-652-42) / 30 TABLET, FILM COATED in 1 BOTTLE",
"package_ndc": "65757-652-42",
"identifierStatus": "well-formed",
"marketing_start_date": "20210920"
}
],
"productId": "65757-652_44ae69cc-b9a6-4658-90fa-1dbef1e97eb4",
"useDomain": "unknown",
"dosageForm": "TABLET, FILM COATED",
"productNdc": "65757-652",
"deaSchedule": null,
"genericName": "olanzapine and samidorphan L-malate",
"productType": "HUMAN PRESCRIPTION DRUG",
"listingStatus": "present-in-source-snapshot",
"targetSpecies": [],
"approvalStatus": "not-established-by-ndc-listing",
"labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
"marketingEndDate": null,
"activeIngredients": [
{
"name": "OLANZAPINE",
"strength": "10 mg/1"
},
{
"name": "SAMIDORPHAN L-MALATE",
"strength": "10 mg/1"
}
],
"applicationNumber": "NDA213378",
"marketingCategory": "NDA",
"stateRestrictions": {
"status": "not-collected",
"observations": []
},
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "us.fda.ndc"
},
"marketingStartDate": "20210920",
"targetSpeciesStatus": "not-reported",
"prescriptionCategory": "prescription-or-restricted",
"harmonizedIdentifiers": {
"nui": [
"N0000175430"
],
"unii": [
"0AJQ5N56E0",
"N7U69T4SZR"
],
"rxcui": [
"2570392",
"2570398",
"2570399",
"2570401",
"2570402",
"2570404",
"2570405",
"2570407"
],
"spl_set_id": [
"32ffddd1-4e2b-45d9-9b36-bb730167ec80"
],
"pharm_class_epc": [
"Atypical Antipsychotic [EPC]"
],
"manufacturer_name": [
"Alkermes, Inc."
],
"is_original_packager": [
true
]
},
"listingExpirationDate": "20271231"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=us" \
--data-urlencode "sourceId=us.fda.ndc" \
--data-urlencode "id=us:fda:ndc:65757-652_44ae69cc-b9a6-4658-90fa-1dbef1e97eb4"